AGL29 Antibody

Nomenclature Clarification

The term "AGL29" does not correspond to any:

• Established gene symbol in the HUGO Gene Nomenclature Committee (HGNC) database

• Protein target in UniProt or NCBI Protein databases

• Antibody clone in commercial catalogs (e.g., R&D Systems, Abcam, Thermo Fisher Scientific)

Notably, the alphanumeric string "AGL29" bears similarity to:

• AG129 mice (immunodeficient models used in dengue virus research)

• Galectin-9 (Gal-9) antibodies (e.g., clones AF2045, EPR22214, EPR23853-132)

AG129 Mouse Model

AG129 mice lack interferon-α/β and -γ receptors and are used to study antibody-mediated immunity against viruses like dengue :

Galectin-9 (Gal-9) Antibodies

Gal-9 antibodies are well-characterized reagents for immunological research :

Key functional roles of Gal-9 antibodies include:

• Detecting isoforms involved in T-cell regulation

• Identifying pathological biomarkers in autoimmune diseases

Therapeutic Antibody Landscape

While AGL29 remains unverified, the broader field of antibody therapeutics includes:

• Antibody-Drug Conjugates (ADCs): 10 FDA-approved agents as of 2025, primarily using IgG1 backbones

• Anti-Infective Antibodies: e.g., EVUSHELD (tixagevimab/cilgavimab) for COVID-19 prophylaxis

Recommendations for Further Inquiry

1. Verify Target Identity: Confirm if "AGL29" refers to a proprietary/internal designation for a known antigen (e.g., Galectin-9, CD19).

2. Explore Orthogonal Resources:

   • Patent Databases: USPTO or WIPO for unpublished antibody sequences

   • Preprint Servers: bioRxiv, medRxiv for emerging data